LLY compared with DRMA: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

DRMADermata Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

DRMADermata Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No shared counterparties.

Only DRMA 2

—Reka-Farmunlistedsupplier

—Revance Therapeuticsunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

LLYELI Lilly & Co

1,420.21▲+0.77%

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

DRMADermata Therapeutics, Inc.

0.84▼−0.60%

Regular sessionNov 4 '26

Mkt cap$3.4MRevenue—Revenue—

Compare

Regular sessionNov 4 '26

LLYELI Lilly & Co

DRMADermata Therapeutics, Inc.

1,420.21▲+0.77%

Price

0.84▼−0.60%

$1.3T

Mkt cap

$3.4M

Q3 FY26$24.4B

Revenue

—

FY25$65.2B

Revenue

—

LLY1,420.21▲+0.77%vsDRMA0.84▼−0.60%Regular sessionNov 4 '26